A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma

Aminah Jatoi, Neil Ellison, Patrick A. Burch, Jeff A Sloan, Shaker R. Dakhil, Paul Novotny, Winston Tan, Tom R. Fitch, Kendrith M. Rowland, Charles Y F Young, Patrick J. Flynn

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

BACKGROUND. Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. METHODS. This study, which was conducted by the North Central Cancer Treatment Group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (PSA) elevation with hormone therapy. Continued use of luteinizing hormone-releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long-acting antiandrogen therapy in the preceding 6 weeks. Patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. Each dose contained 100 calories and 46 mg of caffeine. Patients were monitored monthly for response and toxicity. RESULTS. Tumor response, defined as a decline ≥ 50% in the baseline PSA value, occurred in a single patient, or 2% of the cohort (95% confidence interval, 1-14%). This one response was not sustained beyond 2 months. At the end of the first month, the median change in the PSA value from baseline for the cohort increased by 43%. Green tea toxicity, usually Grade 1 or 2, occurred in 69% of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. However, six episodes of Grade 3 toxicity and one episode of Grade 4 toxicity also occurred, with the latter manifesting as severe confusion. CONCLUSIONS. Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)1442-1446
Number of pages5
JournalCancer
Volume97
Issue number6
DOIs
StatePublished - Mar 15 2003

Fingerprint

Tea
Androgens
Prostate
Carcinoma
Prostate-Specific Antigen
Confusion
Therapeutics
Antineoplastic Agents
Androgen Antagonists
Sleep Initiation and Maintenance Disorders
Caffeine
Gonadotropin-Releasing Hormone
Nausea
Abdominal Pain
Vomiting
Fatigue
Epidemiologic Studies
Diarrhea
Neoplasms
Hormones

Keywords

  • Alternative therapy
  • Epigallocatechin-3-gallate
  • Green tea
  • Polyphenols
  • Prostate carcinoma
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. / Jatoi, Aminah; Ellison, Neil; Burch, Patrick A.; Sloan, Jeff A; Dakhil, Shaker R.; Novotny, Paul; Tan, Winston; Fitch, Tom R.; Rowland, Kendrith M.; Young, Charles Y F; Flynn, Patrick J.

In: Cancer, Vol. 97, No. 6, 15.03.2003, p. 1442-1446.

Research output: Contribution to journalArticle

Jatoi, A, Ellison, N, Burch, PA, Sloan, JA, Dakhil, SR, Novotny, P, Tan, W, Fitch, TR, Rowland, KM, Young, CYF & Flynn, PJ 2003, 'A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma', Cancer, vol. 97, no. 6, pp. 1442-1446. https://doi.org/10.1002/cncr.11200
Jatoi, Aminah ; Ellison, Neil ; Burch, Patrick A. ; Sloan, Jeff A ; Dakhil, Shaker R. ; Novotny, Paul ; Tan, Winston ; Fitch, Tom R. ; Rowland, Kendrith M. ; Young, Charles Y F ; Flynn, Patrick J. / A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. In: Cancer. 2003 ; Vol. 97, No. 6. pp. 1442-1446.
@article{db554bb1e6e442f4b10289faccb066ed,
title = "A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma",
abstract = "BACKGROUND. Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. METHODS. This study, which was conducted by the North Central Cancer Treatment Group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (PSA) elevation with hormone therapy. Continued use of luteinizing hormone-releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long-acting antiandrogen therapy in the preceding 6 weeks. Patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. Each dose contained 100 calories and 46 mg of caffeine. Patients were monitored monthly for response and toxicity. RESULTS. Tumor response, defined as a decline ≥ 50{\%} in the baseline PSA value, occurred in a single patient, or 2{\%} of the cohort (95{\%} confidence interval, 1-14{\%}). This one response was not sustained beyond 2 months. At the end of the first month, the median change in the PSA value from baseline for the cohort increased by 43{\%}. Green tea toxicity, usually Grade 1 or 2, occurred in 69{\%} of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. However, six episodes of Grade 3 toxicity and one episode of Grade 4 toxicity also occurred, with the latter manifesting as severe confusion. CONCLUSIONS. Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma.",
keywords = "Alternative therapy, Epigallocatechin-3-gallate, Green tea, Polyphenols, Prostate carcinoma, Toxicity",
author = "Aminah Jatoi and Neil Ellison and Burch, {Patrick A.} and Sloan, {Jeff A} and Dakhil, {Shaker R.} and Paul Novotny and Winston Tan and Fitch, {Tom R.} and Rowland, {Kendrith M.} and Young, {Charles Y F} and Flynn, {Patrick J.}",
year = "2003",
month = "3",
day = "15",
doi = "10.1002/cncr.11200",
language = "English (US)",
volume = "97",
pages = "1442--1446",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma

AU - Jatoi, Aminah

AU - Ellison, Neil

AU - Burch, Patrick A.

AU - Sloan, Jeff A

AU - Dakhil, Shaker R.

AU - Novotny, Paul

AU - Tan, Winston

AU - Fitch, Tom R.

AU - Rowland, Kendrith M.

AU - Young, Charles Y F

AU - Flynn, Patrick J.

PY - 2003/3/15

Y1 - 2003/3/15

N2 - BACKGROUND. Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. METHODS. This study, which was conducted by the North Central Cancer Treatment Group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (PSA) elevation with hormone therapy. Continued use of luteinizing hormone-releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long-acting antiandrogen therapy in the preceding 6 weeks. Patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. Each dose contained 100 calories and 46 mg of caffeine. Patients were monitored monthly for response and toxicity. RESULTS. Tumor response, defined as a decline ≥ 50% in the baseline PSA value, occurred in a single patient, or 2% of the cohort (95% confidence interval, 1-14%). This one response was not sustained beyond 2 months. At the end of the first month, the median change in the PSA value from baseline for the cohort increased by 43%. Green tea toxicity, usually Grade 1 or 2, occurred in 69% of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. However, six episodes of Grade 3 toxicity and one episode of Grade 4 toxicity also occurred, with the latter manifesting as severe confusion. CONCLUSIONS. Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma.

AB - BACKGROUND. Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. METHODS. This study, which was conducted by the North Central Cancer Treatment Group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (PSA) elevation with hormone therapy. Continued use of luteinizing hormone-releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long-acting antiandrogen therapy in the preceding 6 weeks. Patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. Each dose contained 100 calories and 46 mg of caffeine. Patients were monitored monthly for response and toxicity. RESULTS. Tumor response, defined as a decline ≥ 50% in the baseline PSA value, occurred in a single patient, or 2% of the cohort (95% confidence interval, 1-14%). This one response was not sustained beyond 2 months. At the end of the first month, the median change in the PSA value from baseline for the cohort increased by 43%. Green tea toxicity, usually Grade 1 or 2, occurred in 69% of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. However, six episodes of Grade 3 toxicity and one episode of Grade 4 toxicity also occurred, with the latter manifesting as severe confusion. CONCLUSIONS. Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma.

KW - Alternative therapy

KW - Epigallocatechin-3-gallate

KW - Green tea

KW - Polyphenols

KW - Prostate carcinoma

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0037443797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037443797&partnerID=8YFLogxK

U2 - 10.1002/cncr.11200

DO - 10.1002/cncr.11200

M3 - Article

C2 - 12627508

AN - SCOPUS:0037443797

VL - 97

SP - 1442

EP - 1446

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -